通过氨基酸共接种的环氧金属有机框架,涂上大豆型多糖,通过对氨酸有反应的黄素输送
Shumin Wang1, Shengnan Wang2, Xiuzhi Cao1
1College of Food Science and Technology, Bohai University, Jinzhou 121013, China.
Food chemistry
|March 21, 2025
概括
一个新的大豆覆盖多糖的金属有机框架 (Cys-γ-CD-MOF@SHP) 能够有针对性的释放黄素. 这种新型载体提高了生物可用性,并减少了疏水化合物的副作用.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 黄素 (Cur) 输送受到生物可用性差以及潜在副作用的限制.
- 开发有针对性的输送系统对于提高治疗疗效至关重要.
- 金属有机框架 (MOF) 由于其可调节的结构,具有作为药物载体的潜力.
研究的目的:
- 设计一种新的金属有机框架 (Cys-γ-CD-MOF) 用于谷 (GSH) 触发的黄素释放.
- 用大豆多糖化物 (SHP) 覆盖MOF,以提高生物可用性和减少副作用.
- 评估开发的载体系统的装载,封装和释放特性.
主要方法:
- 合成Cys-γ-CD-MOF及其随后的SHP涂层.
- 使用X射线衍射 (XRD) 和扫描电子显微镜 (SEM) 进行表征.
- 在优化条件下确定黄素加载和封装效率.
- 在实验室释放研究中,研究了GSH的存在和缺乏.
主要成果:
- SHP涂层没有影响Cys-γ-CD-MOF的结晶性;SEM证实了立方形态.
- 在1:3的Cur-to-carrier比率下,达到51.99%的最大黄荷载和封装效率.
- 在GSH溶液中,Cys-γ-CD-MOF@SHP表明选择性黄素释放,在24小时内达到56.39%的累积释放.
结论:
- Cys-γ-CD-MOF@SHP是一种有前途的载体,可以有针对性地提供黄素.
- SHP涂层增强了生物可用性,并减少了潜在的不良影响.
- 该系统有可能提供其他疏水生物活性化合物.
相关概念视频
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
122
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
122
Drug Metabolism: Phase II Reactions
3.5K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.5K


